B experienced treatment-related adverse events, most commonly dermatitis acneiform (76.7%). Eighteen grade ≥3 treatment-related adverse events and five serious adverse events occurred (cardiac arrest, lung infection, interstitial lung disease, toxic skin eruption, blood creatinine increase). Two patients had treatment-related adverse events resulting in death (cardiac arrest and blood creatinine increase). Five patients in Part B had a best overall response of partial response, 12 stable diseases and 12 disease progression (1 not evaluable). The objective response rate was 16.7% (95% CI: 5.6%-34.7%). Sym004 therapy was well tolerated with no dose-limiting toxicities at any dose studied. Evidence of antitumor activity was seen in patients with esophageal squamous cell carcinoma. ClinicalTrials.gov Identifier: NCT01955473.
toxicity. 1 A significant unmet need for more effective therapies for ESCC in Japan and elsewhere therefore remains.
Improved understanding of the molecular biology of cancer has seen the development of targeted therapies in recent years, with some remarkable successes documented. The epidermal growth factor receptor (EGFR) has been identified as an important oncogenic driver in several tumor types including ESCC, 2, 3 for which aberrant EGFR activity is associated with aggressive disease and poor clinical outcome. 2, [4] [5] [6] Aberrant EGFR activity in tumors can arise through gene amplification, somatic mutation, overexpression of EGFR protein, or increased exposure to ligands. 7 EGFR overexpression occurs in 32%-86% of ESCCs. [8] [9] [10] Agents targeting the EGFR signaling pathway have proven effective in the treatment of various solid tumors with aberrant EGFR activity. 3 Two anti-EGFR antibodies, cetuximab and panitumumab, are approved by the US Food and Drug Administration for treatment of colorectal cancer (CRC), and cetuximab is also approved for the treatment of head and neck cancer. 11, 12 Each targets a different epitope in the extracellular domain III of EFGR and inhibits signaling by antagonizing ligand binding. 13, 14 Cetuximab can also induce antibody-dependent cellular cytotoxicity (ADCC), an activity which may contribute to its clinical efficacy. 15 However, EGFR signaling may persist in tumors exposed to cetuximab or panitumumab through ligand-independent activation. Furthermore, tumors can acquire resistance to anti-EGFR antibody therapy through mutation of the EGFR antibody-binding epitopes. Anti-EGFR antibodies less susceptible to these limitations may be more effective anticancer therapies.
Sym004 is a 1:1 mixture of 2 recombinant human/mouse chimeric IgG1 antibodies (mAb992 and mAb1024) directed against nonoverlapping epitopes in the extracellular domain of EGFR. This combination was selected following systematic testing of antibody combinations for the ability to inhibit cancer cell growth in vivo and in vitro. 16 Unlike cetuximab and panitumumab, Sym004 can induce rapid internalization and degradation of EGFR. 17 This leads to inhibition of both ligand-dependent and ligand-independent EGFR activity.
Sym004 also exhibits potent ADCC and complement-mediated cytotoxicity in vitro. 16 Furthermore, because Sym004 targets two separate EGFR epitopes, complete resistance to Sym004 is unlikely to develop through mutation of EGFR. These properties are thought to contribute to the greater efficacy of Sym004 compared to the comparator cetuximab in preclinical models. 18 Sym004 has also demonstrated antitumor activity in models of acquired cetuximab resistance, 19 including examples where resistance arises through mutation of EGFR. 20 Clinically, Sym004 has shown the evidence of efficacy in patients with squamous cell carcinoma of the head and neck 21 and in patients with CRC, 22 including one with acquired resistance to cetuximab. 20 We therefore hypothesized that Sym004 would be active against ESCC driven by oncogenic EGFR. To test this hypothesis, we conducted a phase I trial to establish the safety, tolerability, pharmacokinetics and preliminary antitumor activity of Sym004 in Japanese patients with solid tumors, with an expansion cohort of patients with ESCC.
| MATERIALS AND METHODS

| Study design and treatment
This was a phase I, open label, single-arm study of Sym004 (trial number EMR200637-001). The trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonization guideline for Good Clinical Practice (GCP), the Japanese ministerial ordinance on GCP, and all other applicable regulations.
The trial consisted of two parts, with dose escalation (Part A) based on a traditional "3 + 3" design followed by expansion at the recommended phase II dose (RP2D) established in Part A (Part B). 
| Pharmacokinetics
Blood samples for PK analysis were taken in Week 1 and Week 4 (Week 5 for patients receiving Sym004 biweekly) before infusion, after infusion, and at +4, +8, +12, and 24 hours (and +48 hours, Week 1 only). Additional blood samples were taken before infusion in all other weeks up to Week 8 and during follow-up assessment (4 and 8 weeks after final dose), and after infusion in Week 2 (weekly regimens) and Week 3 (all regimens). Serum concentrations of both Sym004 component antibodies were determined using validated bioanalytical methods.
Non-compartmental PK parameters were calculated using Phoe-
higher. For each patient, the following parameters were determined as appropriate: the area under the curve (AUC) from start of first infusion to 168 hours (AUC (0-168 h) ); AUC from start of first infusion to the last sampling time at which the concentration was greater than or equal to the lower limit of quantification (AUC (0-last) ); half- (V ss ); maximum concentration (C max ); trough concentration (C trough );
and time to C max (t max ). For patients receiving the biweekly regimen, AUC from the start of infusion to 336 hours (AUC (0-336) ) and AUC from start of first infusion extrapolated to infinity (AUC (0-inf) ) were determined instead of AUC (0-168 h) and AUC (0-last) , respectively.
| Statistical plan
The planned sample size of 54 patients (24 in Part A and 30 in Part B) meant that there was a 95% probability of identifying a potentially previously unrecognized TEAE occurring at a true incidence of 5.4%.
The primary endpoints were DLT and TEAEs. Secondary endpoints were PK, Pd, antitumor activity, and immunogenicity. Summary statistics, including mean values, frequencies, percentages, and measures of variation, were calculated for patient cohorts and combined groups as appropriate.
The safety analysis set included all subjects from Parts A and B who received at least 1 dose of Sym004. To be included in the efficacy analysis set, patients were additionally required to 
Number
All statistical analyses were performed using SAS ® v9.2 (SAS Institute Inc., Cary, NC, USA). The best overall response rate and the disease control rate were estimated along with 95% confidence intervals using the method of Clopper and Pearson. Progression-free survival and time to progression were estimated using the KaplanMeier method.
| RESULTS
| Patient population
A total of 51 patients were enrolled. The first patient's first visit occurred on 30 October 2013; the last patient's last visit was 30
October 2015. Baseline patient characteristics are shown in Table 1 .
| Safety
The incidence of TEAEs is shown in Table 2 . No DLTs occurred during Part A. All patients experienced at least 1 treatment-related TEAE, the most frequently reported being dermatitis acneiform (n = 43, 84.3%), hypomagnesemia (n = 39, 76.5%), and dry skin (n = 25, 49%). A total of 24 (47.1%) patients experienced at least 1 grade ≥3 treatment-related TEAE, and 5 (9.8%) experienced at least 1 grade ≥4 treatment-related TEAE. Those occurring in ≥2 patients are listed in Table 2 . Most patients (n = 45, 88.2%) completed study treatment and discontinued the trial due to progressive disease (n = 44, 86.3%) or death (n = 1, 2.0%) at the time of data cut-off. The other reasons of discontinuation were TEAEs (n = 3, 5.9%), withdrawal of consent (n = 2, 3.9%) or other reasons (n = 1, 2.0%).
Based on these data, the SMC set the Sym004 dose for Part B at 12 mg/kg weekly, below the highest dose tested of 18 mg/kg biweekly, to reduce the risk of severe TEAEs.
| Antitumor activity
Sym004 showed signs of efficacy, with an overall objective response rate (complete plus partial response) in Parts A and B of 13.7% and an objective response rate in patients in Part B of 16.7% (Table 3 ).
The duration of response for patients in Part B is shown in Figure 1 .
In Part B, median progression-free survival (defined as the time from first dose until disease progression or death) was 9. 
| Pharmacodynamics
No detectable Pd effects of Sym004 were observed from the analysis of EGFR expression/amplification in paired biopsies of either skin or tumor.
| Biomarkers
Epidermal growth factor receptor was assessed as an exploratory biomarker by IHC and FISH. In part B, 13 paired tumor samples were available. The H-score of 7 predose samples was
Geometric mean (GCV%)
AUC 0-inf (μg.h/mL) AUC 0-inf , area under the curve from start of first infusion extrapolated to infinity; C max , maximum concentration; t max , time to C max ; t 1/2 , half-life; CL, clearance; V z , apparent volume of distribution during the terminal phase; GCV%, geometric coefficient of variation; ND, not determined. AUC 0-inf , area under the curve from start of first infusion extrapolated to infinity; C max , maximum concentration; t max , time to C max ; t 1/2 , half-life; CL, clearance; V z , apparent volume of distribution during the terminal phase; GCV%, geometric coefficient of variation; ND, not determined. | 3259 in the range 200-300, of 1 sample was 100 to <200, and was missing for 5. At week 4, the H-score of 2 samples was 200-300, of 4 was 100 to <200, and was missing for 7. No tumor samples were EGFR FISH-positive, 7 were negative, and data for 6 were missing.
| Immunogenicity
No anti-Sym004 antibodies were found in any of the 170 patient serum samples that were screened.
| DISCUSSION
In this phase I study conducted in Japanese patients with solid tumors, doses of Sym004 up to 18 mg/kg biweekly were explored.
No DLTs were observed at any dose, so an MTD was not established. Although the trial protocol permitted a dose of 18 mg/kg biweekly to be used in the extension study (Part B), a dose of 12 mg/kg weekly was chosen to limit the severity and incidence of treatment-related TEAEs, which occurred in all patients (dermatitis acneiform, hypomagnesemia, and dry skin) and were consistent with anti-EGFR antibody class effects. [23] [24] [25] 28 has the potential to improve response rates. 29 The exclusion of patients with oncogenic alterations F I G U R E 2 Mean (±SD) serum concentration-time profiles for mAb1024 and mAb992 after (A) the 1st (wk 1) and 4th (wk 4) weekly infusions and (B) the 1st (wk 1) and 3rd (wk 5) weekly infusions (semilogarithmic scale)
potentially conferring resistance to EGFR therapy, eg, KRAS mutations, could also improve response rates. 27 Whether Sym004 is more effective in tumors with EGFR amplification or EGFR overexpression requires further study.
The pharmacokinetics of Sym004 determined in this study were comparable with those obtained in non-Japanese patients with CRC 22 and its tolerability at all dose levels was confirmed.
Both the 12 mg/kg weekly and 18 mg/kg biweekly doses were candidate RP2Ds for both Japanese and global patients. The 12 mg/kg dose provides the highest drug exposure and, while unsurprisingly all SAEs were observed in patients treated at this dose, it was selected as the RP2D to be adopted in phase II trials of Sym004.
Monoclonal anti-EGFR antibodies have demonstrated activity in preclinical models of ESCC, [30] [31] [32] and when given in combination with chemotherapy and radiotherapy have shown signs of efficacy in patients with esophageal cancer. 33, 34 Nevertheless, phase II/III trials of gefitinib alone and cetuximab in combination with chemoradiotherapy for the treatment of patients with esophageal cancer failed to demonstrate efficacy. 35, 36 In the context of the results of clinical trials of single-agent therapy in patients with refractory esophageal cancer, which have shown response rates of 15%-17% (nivolumab), 37, 38 the antitumor activity of Sym004 therapy reported in this study is promising but needs to be confirmed.
We hypothesize that Sym004 may be superior to other anti-EGFR therapies tested in ESCC because Sym004 is a mixture of 2 anti-EGFR monoclonal antibodies targeting different epitopes, providing the specificity of a monoclonal antibody therapy combined with a degree of diversity. This provides antitumor activity in preclinical models that is superior to that of monoclonal antibodies. Unlike engineered antibody-like molecules (eg, bispecific antibodies) diversity is not associated with an increased uncertainty regarding immunogenicity. Further trials are needed to establish whether Sym004 can provide significantly greater benefit to patients with ESCC and other types of tumor compared to currently available therapies.
In conclusion, Sym004 represents a novel antibody-mediated approach to EGFR inhibition. In this trial, we have shown that
Sym004 has an acceptable tolerability and safety profile in Japanese patients with solid tumors, including ESCC, and that this is similar to that established previously in Western patients. 22 The findings demonstrate that further study of Sym004 therapy for the treatment of patients with ESCC may be warranted.
